Looking Beyond FDA Warning Letters to Explore Unforeseen Trouble Spots in eDTCA: A Response to Recent Commentaries

Document Type : Correspondence

Author

Division of Communication, University of Wisconsin-Stevens Point, Stevens Point, WI, USA

Keywords

Main Subjects

Full Text

I would like to take this opportunity to express my deepest gratitude to everyone who responded to my study entitled: “Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters.”1 Scholars from several different fields, including medical science, pharmacy, business, and communication have all participated in the discussion of current issues and the future of direct-to consumer advertising (DTCA), bringing multifaceted viewpoints to bear on prescription drug marketing based on their own disciplines... (Read more...)

References

  1. Kim H. Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters. Int J Health Policy Manag. 2015;4(12):813-821. doi:10.15171/ijhpm.2015.157
  2. Mackey TK. Digital direct-to-consumer advertising: a perfect storm of rapid evolution and stagnant regulation: Comment on “Trouble spots in online direct-to-consumer prescription drug promotion: a content analysis of FDA warning letters.” Int J Health Policy Manag. 2016;5(4):2271-2274. doi:10.15171/ijhpm.2016.11
  3. Mintzes B. The tip of the iceberg of misleading online advertising: Comment on “Trouble spots in online direct-to-consumer prescription drug promotion: a content analysis of FDA warning letters.” Int J Health Policy Manag. 2016;5(5):329-331. doi:10.15171/ijhpm.2016.19
  4. Southwell, Brian G. RDJ. Future challenges and opportunities in online prescription drug promotion research: Comment on “Trouble spots in online direct-to-consumer prescription drug promotion: a content analysis of FDA warning letters.” Int J Health Policy Manag. 2016;5(3):211-213. doi:10.15171/ijhpm.2016.05
  5. Liang BA, Mackey T. Direct-to-consumer advertising with interactive internet media: global regulation and public health issues. J Am Med Assoc. 2011;305(8):824-825. doi:10.1001/jama.2011.203
  6. Gibson S. Regulating direct-to-consumer advertising of prescription drugs in the digital age. Laws. 2014;3(3):410-438.
  7. Wanasika I. the conundrum of online prescription drug promotion: Comment on “Trouble spots in online direct-to-consumer prescription drug promotion: a content analysis of FDA warning letters.” Int J Health Policy Manag. 2016;5(6):391-392. doi:10.15171/ijhpm.2016.33
  8. Dillman Carpentier FR. Considering the future of pharmaceutical promotions in social media: Comment on “Trouble spots in online direct-to-consumer prescription drug promotion: a content analysis of FDA warning letters.” Int J Health Policy Manag. 2016;5(4):283-285. doi:10.15171/ijhpm.2016.15
  9. Rollins BL. Still the Great Debate – “Fair balance” in direct-to-consumer prescription drug advertising: Comment on “Trouble spots in online direct-to-consumer prescription drug promotion: a content analysis of FDA warning letters.” Int J Health Policy Manag. 2016;5(4):287-288. doi:10.15171/ijhpm.2016.17
  10. Sheehan K. Balancing acts: an analysis of Food and Drug Administration letters about direct-to-consumer advertising violations. J Public Policy Mark. 2003;22(2):159-169.
  11. Hoy MG, Park JS. Principles in action: an examination of Food and Drug Administration letters involving violative internet promotions from 1997 to 2012. J Public Policy Mark. 2014;33(2):127-142. doi:10.1509/jppm.12.097
  12. Doran E. Trouble spots in online direct-to-consumer prescription drug promotion: teaching drug marketers how to inform better or spin better? Comment on “Trouble spots in online direct-to-consumer prescription drug promotion: a content analysis of Fda warning letters. Int J Health Policy Manag. 2016;5(5):333-335. doi:10.15171/ijhpm.2016.20
  13. gparisi. FTC to Pharma on Native Advertising: Proceed with Caution. Coalitation for Healthcare Communication website. http://www.cohealthcom.org/2016/04/18/ftc-to-pharma-on-native-advertising-proceed-with-caution/. Accessed June 23, 2016. Published July 1, 2016.

Files

History

  • Receive Date: 20 June 2016
  • Revise Date: 10 July 2016
  • Accept Date: 02 July 2016
  • First Publish Date: 01 October 2016

Share

How to cite

Statistics